- Kristi Powers

A new way of treating bladder cancer is now available to patients in Central Florida via a Phase II randomized trial at the AdventHealth Cancer Institute. This is the only site in Florida, and the first in the U.S., to open this groundbreaking treatment, known as the INTerpath-005 V940 mRNA vaccine Phase II trial.
“This vaccine is precision medicine at its best,” Guru Sonpavde, MD, a medical oncologist at the AdventHealth Cancer Institute, as well as a member of the trial’s global steering committee, recently told Central Florida Health News. “Unlike most trials where all patients receive one specific drug, some of the patients in this trial will receive a new drug customized to target the specific mutated proteins only found in the cancer cells of that patient.”
"This vaccine is precision medicine at its best."
Participants will receive pembrolizumab (KEYTRUDA) combined with the new customized immunotherapy injection. KEYTRUDA alone has previously improved outcomes following surgical removal of aggressive muscle-invasive urothelial cancer.
“This V940 drug is exciting in that it codes for 34 neoantigens (which are new mutated proteins) found only in cancer cells and this is injected into the patient intramuscularly every three weeks for up to nine times,” Dr. Sonpavde shared in a Becker’s Healthcare podcast. “This (drug) is extremely specific immunotherapy which looks highly promising.”
Dr. Sonpavde believes this trial offers a tailored treatment against bladder cancer.
”I’m optimistic the combination drug treatment, the V940 vaccine plus KEYTRUDA, in this trial will be safe and successful and will lead to a Phase III trial,” he recently told the American Hospital Association.
He envisions this custom treatment to become more widely available worldwide soon. Bladder cancer patients don’t have to wait years for access; the trial is now open. Patients need a referral and should ask their doctor if they’re interested.
For more information, contact the AdventHealth Clinical Research GU Coordinator at ORL.GU.ClinicalTrials@AdventHealth.com.
Recent News
Days before competing in the DAYTONA 500, driver Erik Jones visited a Central Florida elementary school to deliver a big surprise.
Students across seven elementary schools in Kansas received more than 1,500 pairs of new shoes and 3,000 pairs of new socks.
AdventHealth Centra Care Medical Director Tim Hendrix, MD, explains the symptoms of and the prevention strategies for the "quad-demic" of illnesses going around.
A coalition that supports health-care professionals in achieving personal and professional fulfillment while enhancing patient care has announced its new name.
AdventHealth has reached a major milestone by welcoming its 100,000th team member to the health system’s skilled and compassionate workforce.
AdventHealth Cancer Institute Winter Park's infusion center provides a warm and supportive environment, complete with recliners, TVs, nourishment stations and a private room.
AdventHealth Waterman's new boutique offers free wigs to women experiencing medical-related hair loss.
AdventHealth Chief Investment Officer Rob Roy discusses the organization's leadership in environmental sustainability on The Sustainable Finance Podcast.
The Freytag Cancer Center brings advanced medical treatments and compassionate care to one of the fastest-growing parts of Florida.
AdventHealth President and CEO Terry Shaw, who will retire in July, reflects on his career and shares the six lessons that have stuck with him the most.
AdventHealth has named Eric Lunde president and chief executive officer for AdventHealth Fish Memorial, located in Orange City, Florida, effective Feb. 9, 2025.
Across AdventHealth, a community of team members unites under a shared mission, serving more than 8 million patients annually.